A liquid chromatography-mass spectrometry method based on class characteristic fragmentation pathways to detect the class of indole-derivative synthetic cannabinoids in biological samples

Analytica Chimica Acta

Volumn 837, Issue , 2014, Pages 70-82

  Mazzarino, Monica ^a   Torre, Xavier de la ^a   Botrè, Francesco ^a,b  

^a Laboratorio Antidoping   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Anti doping analysis; Drug analysis; Liquid chromatography mass spectrometry; Precursor ion scan; Structural marker; Synthetic cannabinoids

Indexed keywords

BLOOD; ELECTROSPRAY IONIZATION; ENZYMATIC HYDROLYSIS; IONS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETERS; MOLECULAR STRUCTURE; POLYCYCLIC AROMATIC HYDROCARBONS; PRECIPITATION (CHEMICAL);

ANTI-DOPING ANALYSIS; DRUG ANALYSIS; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; PRECURSOR-ION SCAN; STRUCTURAL MARKER; SYNTHETIC CANNABINOIDS;

ORGANIC POLYMERS;

1 BUTYL 3 (1 NAPHTHOYL)INDOLE; 1 PENTYL 2 METHYL 3 (1 NAPHTHOYL)INDOLE; 1 PENTYL 2 METHYL 3 (4 METHOXY 1 NAPHTHOYL)INDOLE; 1 PENTYL 3 (2 BROMOPHENYLACETYL)INDOLE; 1 PENTYL 3 (2 METHOXYPHENYLACETYL)INDOLE; 1 PENTYL 3 (2 METHYLPHENYLACETYL)INDOLE; 1 PENTYL 3 (3 METHOXYPHENYLACETYL)INDOLE; 1 PENTYL 3 (4 ETHYL 1 NAPHTHOYL)INDOLE; 1 PENTYL 3 (4 ETHYLNAPHTHOYL)INDOLE; 1 PENTYL 3 (4 METHYL 1 NAPHTHOYL)INDOLE; 1 PENTYL 3 (8 BROMO 1 NAPHTHOYL)INDOLE; 1 PROPHYL 2 METHYL 3 (1 NAPHTHOYL)INDOLE; 1 [2 (4 MORPHOLINYL)ETHYL] 3 (1 NAPHTHOYL)INDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (1 NAPHTHOYL) 1 PENTYLINDOLE; AMINOALKYLINDOLE DERIVATIVE; BENZOYLINDOLE DERIVATIVE; CANNABINOID DERIVATIVE; DRUG METABOLITE; INDOLE DERIVATIVE; NAPHTHOYLINDOLE DERIVATIVE; PHENYLACETYLINDOLE DERIVATIVE; UNCLASSIFIED DRUG; CANNABINOID;

ARTICLE; BLOOD; BODY FLUID; CENTRIFUGATION; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; CONTROLLED STUDY; ELECTROSPRAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; PRECURSOR; PRIORITY JOURNAL; SALIVA; TANDEM MASS SPECTROMETRY; URINE; CHEMISTRY; FRACTIONATION; MASS SPECTROMETRY; METABOLISM; PROCEDURES;

CANNABINOIDS; CHEMICAL FRACTIONATION; CHROMATOGRAPHY, LIQUID; HUMANS; INDOLES; MASS SPECTROMETRY; MICROSOMES, LIVER; MOLECULAR STRUCTURE;

EID: 84903815254     PISSN: 00032670     EISSN: 18734324     Source Type: Journal    
DOI: 10.1016/j.aca.2014.06.003     Document Type: Article

References (51)

1. Ameri A. The effects of cannabinoids on the brain. Prog. Neurobiol. 1999, 58:315-348.
2. Campos D.R., Yonamine M., de Moraes Moreau R.L. Marijuana as doping in sports. Sport Med. 2003, 33:395-399.
3. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., Pertwee R.G. International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 2002, 54:161-202.
4. Marriott K.S., Huffman J.W. Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor. Curr. Top. Med. Chem. 2008, 8:187-204.
5. Huffman J.W., Dai D., Martin B.R., Compton D.R. Design, synthesis and pharmacology of cannabimimetic indoles. Bioorg. Med. Chem. Lett. 1994, 4:563-566.
6. Lambert D.M., Fowler C.J. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J. Med. Chem. 2005, 48:5059-5087.
7. Huffman J.W., Padgett L.W. Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes. Curr. Med. Chem. 2005, 12:1395-1411.
8. Di Marzo V., De Petrocellis L. Plant, synthetic, and endogenous cannabinoids in medicine. Annu. Rev. Med. 2006, 57:553-574.
9. Pavlopoulos S., Thakur G.A., Nikas S.P., Makriyannis A. Cannabinoid receptors as therapeutic targets. Curr. Pharm. Des. 2006, 12:1751-1769.
10. Seely K.A., Prather P.L., James L.P., Moran J.H. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse?. Mol. Interv. 2011, 11:36-51.
11. Chang C.E., Ai R., Gutierrez M., Marsella M.J. Homology modelling of cannabinoid receptors: discovery of cannabinoid analogues for therapeutic use. Methods Mol. Biol. 2012, 819:595-613.
12. Carroll F., Lewin A., Mscarella W., Seltzman H., Reddy P. Designer drugs: a medicinal chemistry perspective. Ann. N. Y. Acad. Sci. 2012, 1248:18.
13. Mustata C., Torrens M., Pardo R., Pérez C., Farré M. Spice drugs: cannabinoids as a new designer drugs. Adicciones 2009, 21:181-186.
14. Auwärter V., Dresen S., Weinmann W., Müller M., Pütz M., Ferreirós N. 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs?. J. Mass Spectrom. 2009, 44:832-837.
15. Lindigkeit R., Boehme A., Eiserloh I., Luebbecke M., Wiggermann M., Ernst L., Beuerle T. Spice: a never ending story?. Forensic Sci. Int. 2009, 191:58-63.
16. Griffiths P., Sedefov R., Gallegos A., Lopez D. How globalization and market innovation challenge how we think about and respond to drug use: 'spice' a case study. Addiction 2010, 105:951-953.
17. Seely K.A., Lapoint J., Moran J.H., Fattore L. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 39:234-243.
18. Bretteville-Jensen A.L., Tuv S.S., Bulgari O.R., Fjeld B., Bachs L. Synthetic cannabinoids and cathinones: prevalence and markets. Forensic Sci. Rev. 2013, 25:7-26.
19. Hudson S., Ramsey J. The emergence and analysis of synthetic cannabinoids. Drug Test. Anal. 2011, 3:466-478.
20. Uchiyama N., Kikura-Hanajiri R., Kawahara N., Haishima Y., Goda Y. Identification of a cannabinoid analog as a new type of designer drug in a herbal product. Chem. Pharm. Bull. 2009, 57:439-441.
21. Dresen S., Ferreirós N., Pütz M., Westphal F., Zimmermann R., Auwärter V. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J. Mass Spectrom. 2010, 45:1186-1194.
22. Uchiyama N., Kikura-Hanajiri R., Ogata J., Goda Y. Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci. Int. 2010, 198:31-38.
23. Penn H.J., Langman L.J., Unold D., Shields J., Nichols J.H. Detection of synthetic cannabinoids in herbal incense products. Clin. Biochem. 2011, 44:1163-1165.
24. Gottardo R., Chiarini A., Dal Prà I., Seri C., Rimondo C., Serpelloni G., et al. Direct screening of herbal blends for new synthetic cannabinoids by MALDI-TOF MS. J. Mass Spectrom. 2012, 47:141-146.
25. Hutter M., Kneisel S., Auwärter V., Neukamm M.A. Determination of 22 synthetic cannabinoids in human hair by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 2012, 903:95-101.
26. Salomone A., Gerace E., D'Urso F., Di Corcia D., Vincenti M. Simultaneous analysis of several synthetic cannabinoids, THC, CBD, CBN in hair by ultra-high performance liquid chromatography-tandem mass spectrometry. Method validation and application to real samples. J. Mass Spectrom. 2012, 47:604-610.
27. Kim J., In S., Park Y., Park M., Kim E., Lee S. Deposition of JWH-018, JWH-073 and their metabolites in hair and effect of hair pigmentation. Anal. Bioanal. Chem. 2013, 405:9769-9778.
28. Coulter C., Garnier M., Moore C. Synthetic cannabinoids in oral fluid. J. Anal. Toxicol. 2011, 35:424-430.
29. Kneisel S., Auwärter V., Kempf J. Analysis of 30 synthetic cannabinoids in oral fluid using liquid chromatography-electrospray ionization tandem mass spectrometry. Drug Test. Anal. 2013, 657:657-669.
30. Dresen S., Kneisel S., Weinmann W., Zimmermann R., Auwärter V. Development and validation of a liquid chromatography-tandem mass spectrometry method for the quantification of synthetic cannabinoids of the aminoalkylindole type and methanandamide in serum and its application to forensic samples. J. Mass Spectrom. 2011, 46:163-171.
31. Kacinko S.L., Xu A., Homan J.W., McMullin M.M., Warrington D.M., Logan B.K. Development and validation of a liquid chromatography-tandem mass spectrometry method for the identification and quantification of JWH-018, JWH-073, JWH-019, and JWH-250 in human whole blood. J. Anal. Toxicol. 2011, 35:386-393.
32. Ammann J., McLaren J.M., Gerostamoulos D., Beyer J. Detection and quantification of new designer drugs in human blood: Part 1 - Synthetic cannabinoids. J. Anal. Toxicol. 2012, 36:372-380.
33. Kneisel S., Auwärter V. Analysis of 30 synthetic cannabinoids in serum by liquid chromatography-electrospray ionization tandem mass spectrometry after liquid-liquid extraction. J. Mass Spectrom. 2012, 47:825-835.
34. Hutter M., Broecker S., Kneisel S., Auwärter V. Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in 'herbal mixtures' using LC-MS/MS techniques. J. Mass Spectrom. 2012, 47:54-65.
35. Sobolevsky T., Prasolov I., Rodchenkov G. Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Sci. Int. 2010, 200:141-147.
36. de Brabanter N., Esposito S., Geldof L., Lootens L., Meuleman P., Leroux-Roels G., Deventer K., Van Eenoo P. In vitro and in vivo metabolisms of the synthetic cannabinoid JWH200. Rapid Commun. Mass Spectrom. 2013, 27(18):2115.
37. de Brabanter N., Esposito S., Geldof L., Lootens L., Meuleman P., Leroux-Roels G., Deventer K., Van Eenoo P. In vitro and in vivo metabolisms of 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122). Forensic Toxicol. 2013, 31:212.
38. Wohlfarth A., Scheidweiler K.B., Chen X., Liu H.-F., Huestis M.A. Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC-MS/MS and library search. Anal. Chem. 2013, 85:3730-3738.
39. Moller I., Wintermeyer A., Bender K., Jubner M., Thomas A., Krug O., Schanzer W., Thevis M. Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls. Drug Test. Anal. 2011, 3:609-620.
40. Hudson S., Ramsey J., King L., Timbers S., Maynard S., Dargan P.I., Wood D.M. Use of high-resolution accurate mass spectrometry to detect reported and previously unreported cannabinomimetics in "herbal high" products. J. Anal. Toxicol. 2010, 34:252-260.
41. Sekula K., Zuba D., Stanaszek R. Identification of naphthoylindoles acting on cannabinoid receptors based on their fragmentation patterns under ESI-QTOFMS. J. Mass Spectrom. 2012, 47:632-643.
42. Mazzarino M., Turi S., Botrè F. A screening method for the detection of synthetic glucocorticoids in human urine by liquid chromatography-mass spectrometry based on class characteristic fragmentation pathways. Anal. Bioanal. Chem. 2008, 390:1389-1402.
43. Thevis M., Schänzer W. Current role of LC-MS(/MS) in doping control. Anal. Bioanal. Chem. 2007, 388(7):1351-1358.
44. Thevis M., Geyer H., Mareck U., Schanzer W. Screening for unknown synthetic steroids in human urine by liquid chromatography-tandem mass spectrometry. J. Mass Spectrom. 2005, 40:955-962.
45. Pozo O.J., Deventer K., Van Eenoo P., Delbeke F.T. Efficient approach for the comprehensive detection of unknown anabolic steroids and metabolites in human urine by liquid chromatography-electrospray-tandem mass spectrometry. Anal. Chem. 2008, 80:1709-1720.
46. Thevis M., Kamber M., Schänzer W. Screening for metabolically stable aryl-propionamide-derived selective androgen receptor modulators for doping control purposes. Rapid Commun. Mass Spectrom. 2006, 20:870-876.
47. The World Anti-Doping Code, The 2014 Prohibited List International Standard. World Anti-Doping Agency: Montreal, Canada, 2014. Available at: http://www.wada-ama.org.
48. WADA Technical Document TD2013MRPL (Minimum required performance limits for detection of prohibited substances). World Anti-Doping Agency: Montreal, Canada, 2013. Available at: http://www.wada-ama.org.
49. Zhang Q., Ma P., Cole R.B., Wang G. Identification of in vitro metabolites of JWH-015, an aminoalkylindole agonist for the peripheral cannabinoid receptor (CB2) by HPLC-MS/MS. Anal. Bioanal. Chem. 2006, 386:1345-1355.
50. Wintermeyer A., Möller I., Thevis M., Jübner M., Beike J., Rothschild M.A., Bender K. In vitro phase I metabolism of the synthetic cannabimimetic JWH-018. Anal. Bioanal. Chem. 2010, 398:2141-2153.
51. Botrè F. Drugs of abuse and abuse of drugs in sportsmen: the role of in vitro models to study effects and mechanisms. Toxicol. In Vitro 2003, 17:509-513.